• Rosenblatt, Joseph D (PI)
  • Belldegrun, Arie (PI)
  • McBride, William H. (PI)
  • Shau, Hungyi (PI)
  • Economou, James S. (PI)

Project: Research project

Project Details


This Program explores the use of somatic gene therapy to augment the host
immune response to cancer. The various projects will genetically modify
effector cells to improve their anti-tumor activity or modify tumor cells
to improve immunogenicity. Basic and preclinical investigations will explore methods of optimal gene
transfer into T lymphocytes, macrophages and tumor cells using retroviral
and adeno-associated virus vectors. Mechanistic studies will focus on ways
to improve anti-tumor activity of tumor-infiltrating lymphocytes (TIL) and
macrophages using cytokine genes such as IL-7 and IL-6 and cytotoxin genes
such as perforin and defensin. Efforts to improve tumor immunogenicity
will employ cytokine gene transduction or modulation of MHC expression by
altering oncogene expression. The goal will be to develop genetically-
engineered vaccines capable of stimulating tumor immunity or generating
immune lymphocytes in draining lymph nodes suitable for adoptive
immunotherapy trials. Preclinical animal models, including the use of
SCID/hu mice, will study interactions between genetically modified human
effector and tumor cells in vivo. Clinical trials are proposed for the gene therapy of melanoma, renal
cancer, leukemia and neuroblastoma that directly translate basic and
preclinical efforts. In summary, we plan a comprehensive basic, preclinical, and clinical
program of highly interactive cancer gene therapy projects.
Effective start/end date9/30/9212/31/98


  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health


  • Medicine(all)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.